Dr Reddy’s Labs gets EIR from USFDA

Dr. Reddy’s Laboratories’ active pharmaceutical ingredient (API) manufacturing plant-5 has received an EIR from the USFDA

379
USFDA
Picture: Pixabay

Dr. Reddy’s Laboratories’ active pharmaceutical ingredient (API) manufacturing plant-5 in Miryalaguda of Nalgonda District in Telangana has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA).

“We have received an EIR from US FDA for the facility, indicating closure of the audit, the company said in a BSE filing. The company added that the inspection classification of this facility is determined as voluntary action indicated (VAI).

Also read: Zydus Cadila gets USFDA nod for empagliflozin tablets

Dr. Reddy’s Laboratories is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – pharmaceutical services & active ingredients, global generics and proprietary products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.